Marker Therapeutics Inc (MRKR)

[Lady_luck]

ASH presentation

The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting

--Three abstracts accepted, including oral presentation on multiple myeloma clinical data--

HOUSTON, Nov. 27, 2018 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company, today reported that data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018). The studies describe results achieved using multi-tumor antigen specific T cells that were developed at the Baylor College of Medicine in the laboratories of Dr. Ann Leen and Dr. Juan Vera, and exclusively licensed to Marker.


https://finance.yahoo.com/news/center-cell-gene-therapy-baylor-213200120.html